Tezacaftor, Elexacaftor, Ivacaftor

7 trials 1 recruiting RRespiratory Orphan designation

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

1 Recruiting

4 Completed trials

2 Sponsors

15 Countries

Phase III

Phase II

Phase IV

Phase III: 5 Phase II: 1 Phase IV: 1

Indications tested

Cystic fibrosis 7

Sponsors using this IMP

Vertex Pharmaceuticals Inc. 6 IRCCS Istituto Giannina Gaslini 1

All trials

7 total

A low-intervention prospective-retrospective study to evaluate the pharmacokinetics of elexacaftor/tezacaftor/ivacaftor combination in a Cys… Pending

2024-518785-28-00 Phase IV 1 country IRCCS Istituto Giannina Gaslini
Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis Pending

2025-523400-72-00 Phase II 11 countries Vertex Pharmaceuticals Inc.
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis Subjects 1 Through 11 Years of Age Recruiting

2024-513754-29-00 Phase III 4 countries Vertex Pharmaceuticals Inc.
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Subjects 12 Months of Age and Older Ended

2023-509563-24-00 Phase III 3 countries Vertex Pharmaceuticals Inc.
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended

2024-515637-14-00 Phase III 13 countries Vertex Pharmaceuticals Inc.
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis Subjects 12 to Less Than 24 Months of Age Ended

2023-503230-49-00 Phase III 3 countries Vertex Pharmaceuticals Inc.
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Subjects 2 Years and Older Ended

2024-515606-90-00 Phase III 1 country Vertex Pharmaceuticals Inc.

Showing 1–7 of 7 trials

← All drugs A–Z